Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB12 vs Soliris in Paroxysmal Nocturnal Hemoglobinuria
CTR20201869Phase 3Terminated
- Sponsor
- Samsung Bioepis
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SB12 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Samsung Bioepis. Started Sep 2020; status: terminated.
02
Drugs
SB12
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20201869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201869.